Gene Therapies

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

A $182,500 seizure in Quebec is just the tip of the iceberg, revealing a nationwide struggle against high-tech smuggling, drones, and prison violence.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

A new partnership combines AI-driven precision with deep gene therapy expertise, aiming to overcome critical safety hurdles and redefine treatment for rare diseases.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

The cancer center's prestigious FACT accreditation for bone marrow transplants brings world-class blood cancer treatment closer to home for patients in Georgia.

Mispro's new contract vivarium at Genesis Science Center aims to provide crucial, flexible lab space for San Diego's burgeoning biotech startups.

A new partnership aims to solve one of biotech's biggest challenges, expanding powerful gene therapies beyond the liver to treat a wider range of diseases.

A biotech firm has hatched healthy chicks from artificial eggs, a breakthrough paving the way for de-extinction and a new era in avian conservation.